MDT-AP-0194
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- age_years
- 27
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.260498259
- umap2_2d
- -11.86298996
- umap1_3d
- -3.127791572
- umap2_3d
- 0.376611076
- umap3_3d
- 6.829571769
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MITOTIC_SPINDLE+0.320
- MYC_TARGETS_V1+0.290
- PROTEIN_SECRETION+0.240
- UV_RESPONSE_DN+0.240
- UNFOLDED_PROTEIN_RESPONSE+0.230
- ANDROGEN_RESPONSE+0.220
- HEDGEHOG_SIGNALING+0.180
- PI3K_AKT_MTOR_SIGNALING+0.170
- MYC_TARGETS_V2+0.150
- PEROXISOME+0.090
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.470
- ALLOGRAFT_REJECTION-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
- INFLAMMATORY_RESPONSE-0.410
- INTERFERON_ALPHA_RESPONSE-0.390
- TNFA_SIGNALING_VIA_NFKB-0.390
- MYOGENESIS-0.320
- APICAL_SURFACE-0.310
- COAGULATION-0.310
- COMPLEMENT-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 959c268c-637f-4f39-a254-a505c57e8448 | — | — | 0.853 |
| 2 | MDT-AP-3315 | Med | Medulloblastoma | 0.851 |
| 3 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.847 |
| 4 | SRR26320097 | — | — | 0.846 |
| 5 | TCGA-E9-A1R7-01A-11R-A14M-07 | — | B | 0.844 |
| 6 | TCGA-C8-A12M-01A-11R-A115-07 | — | B | 0.839 |
| 7 | SRR662871 | GTEX | — | 0.828 |
| 8 | e8db6fe2-7a97-4f20-a7e0-9600f0e58800 | — | — | 0.828 |
| 9 | MDT-AP-0188 | Med | Medulloblastoma | 0.820 |
| 10 | TCGA-A8-A08T-01A-21R-A00Z-07 | — | B | 0.820 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MITOTIC_SPINDLE | 0.320 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.240 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.220 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.180 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.170 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.150 | Idelalisib | — uncovered |
| PEROXISOME | 0.090 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.060 | Cobimetinib | — uncovered |
| G2M_CHECKPOINT | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.050 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |